Work

Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz250.010

Authors: R.S. Kristeleit, A.M. Oza, A. Oaknin, C. Aghajanian, A.V. Tinker, O. Tredan, D.M. O’Malley, A. Leary, G.E. Konecny, D. Lorusso, J.I. Weberpals, S. Goble, L. Maloney, T. Cameron, E. Swisher, I.A. McNeish, R. Shapira-Frommer, J.A. Ledermann, R.L. Coleman

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2977615602

FWCI: 0.363

Cites:

Cited by: 8

Related to: 10